Clinical Trial Update: Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating lomustine for bevacizumab-naive recurrent malignant glioma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Lomustine (Lomustine)

Snippet

Sponsor: Annick Desjardins | Conditions: Malignant Glioma (WHO Grade III or IV) | Phase 1 | Status: TERMINATED